Of note, clinical trials using the ECT have been initiated to evaluate the outcome of a sustained cell-based administration of CNTF in patients with ischemic optic neuropathy (ClinicalTrials.gov Identifier: NCT01411657) or glaucoma (ClinicalTrials.gov Identifier: NCT01408472, NCT02862938 and NCT04577300), but no results have been reported until now. Here, CNTF is linked to glaucoma.